The stock of ITeos Therapeutics Inc (NASDAQ: ITOS) has decreased by -1.56 when compared to last closing price of 8.35. Despite this, the company has experienced a 8.16% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-13 that – GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival
Is It Worth Investing in ITeos Therapeutics Inc (NASDAQ: ITOS) Right Now?
Moreover, the 36-month beta value for ITOS is 1.42. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for ITOS is 35.88M and currently, short sellers hold a 7.06% of that float. On May 22, 2025, ITOS’s average trading volume was 812.62K shares.
ITOS’s Market Performance
ITOS’s stock has seen a 8.16% increase for the week, with a 10.34% rise in the past month and a 9.89% gain in the past quarter. The volatility ratio for the week is 5.53%, and the volatility levels for the past 30 days are at 6.94% for ITeos Therapeutics Inc The simple moving average for the past 20 days is 11.09% for ITOS’s stock, with a -9.71% simple moving average for the past 200 days.
Analysts’ Opinion of ITOS
Many brokerage firms have already submitted their reports for ITOS stocks, with Leerink Partners repeating the rating for ITOS by listing it as a “Market Perform.” The predicted price for ITOS in the upcoming period, according to Leerink Partners is $9 based on the research report published on May 14, 2025 of the current year 2025.
ITOS Trading at 21.41% from the 50-Day Moving Average
After a stumble in the market that brought ITOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.08% of loss for the given period.
Volatility was left at 6.94%, however, over the last 30 days, the volatility rate increased by 5.53%, as shares surge +14.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.43% upper at present.
During the last 5 trading sessions, ITOS rose by +8.16%, which changed the moving average for the period of 200-days by -50.39% in comparison to the 20-day moving average, which settled at $7.40. In addition, ITeos Therapeutics Inc saw 7.03% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITOS starting from EcoR1 Capital, LLC, who purchase 3,300,000 shares at the price of $8.00 back on May 15 ’25. After this action, EcoR1 Capital, LLC now owns 10,688,978 shares of ITeos Therapeutics Inc, valued at $26,400,000 using the latest closing price.
EcoR1 Capital, LLC, the 10% Owner of ITeos Therapeutics Inc, purchase 1,658,978 shares at $7.41 during a trade that took place back on May 14 ’25, which means that EcoR1 Capital, LLC is holding 7,388,978 shares at $12,285,562 based on the most recent closing price.
Stock Fundamentals for ITOS
Current profitability levels for the company are sitting at:
- -4.35 for the present operating margin
- 0.99 for the gross margin
The net margin for ITeos Therapeutics Inc stands at -3.74. The total capital return value is set at -0.25. Equity return is now at value -23.68, with -20.30 for asset returns.
Based on ITeos Therapeutics Inc (ITOS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -19.7.
Currently, EBITDA for the company is -159.53 million with net debt to EBITDA at 1.02. When we switch over and look at the enterprise to sales, we see a ratio of 4.66. The receivables turnover for the company is 10.7for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.13.
Conclusion
To wrap up, the performance of ITeos Therapeutics Inc (ITOS) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
